Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) SVP Steven Keith Burke sold 50,506 shares of Akebia Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $106,062.60. Following the transaction, the senior vice president now directly owns 816,234 shares in the company, valued at approximately $1,714,091.40. This trade represents a 5.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Akebia Therapeutics Trading Up 0.9 %
Shares of NASDAQ:AKBA traded up $0.02 on Tuesday, hitting $2.14. The company had a trading volume of 1,343,441 shares, compared to its average volume of 2,507,634. Akebia Therapeutics, Inc. has a 52-week low of $0.80 and a 52-week high of $2.48. The business has a 50 day moving average of $2.00 and a 200 day moving average of $1.67. The company has a market cap of $466.91 million, a PE ratio of -9.30 and a beta of 0.74.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to analysts’ expectations of $45.66 million. During the same period in the prior year, the firm earned ($0.08) EPS. As a group, equities analysts predict that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on AKBA
Institutional Investors Weigh In On Akebia Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC increased its stake in Akebia Therapeutics by 276.1% during the third quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 200,482 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Akebia Therapeutics in the third quarter worth about $534,000. BNP Paribas Financial Markets boosted its position in shares of Akebia Therapeutics by 205.8% in the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 31,137 shares during the period. XTX Topco Ltd purchased a new stake in shares of Akebia Therapeutics in the third quarter worth about $58,000. Finally, State Street Corp boosted its position in shares of Akebia Therapeutics by 24.9% in the third quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company’s stock worth $4,528,000 after buying an additional 683,287 shares during the period. 33.92% of the stock is currently owned by institutional investors and hedge funds.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Recommended Stories
- Five stocks we like better than Akebia Therapeutics
- 5 discounted opportunities for dividend growth investors
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Using the MarketBeat Dividend Yield Calculator
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What is the Shanghai Stock Exchange Composite Index?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.